Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Completed 18 months of study treatment and assessments in Baxter precursor study 160701~* Diagnosis of probable Alzheimer´s Disease (AD)~* Able to comply with testing and infusion regimen (including adequate corrected visual acuity and hearing ability)~* Has a caregiver (study partner) who is willing and able to participate~Main Exclusion Criteria:~* Significant neurological disease other than AD~* Clinically significant cardiac/cardiovascular problems (e.g. uncontrolled blood pressure, atrial fibrillation, heart disease, clotting disorders, strokes, or recent heart attack)~* Contraindication to undergoing MRI (e.g. pacemaker \[with the exception of an MRI-compatible pacemaker\], severe claustrophobia, ferromagnetic implants such as a metal plate)~* Specific findings on brain MRI (microhemorrhages, superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, or multiple lacunae)~* Active malignancy or history of malignancy within 5 years prior to screening with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment~* Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)~* Poorly controlled diabetes~* Serious problems with liver or kidneys~* Known history of hypersensitivity following infusions of human blood or blood components (e.g. human immunoglobulins or human albumin)~* Current or recent treatment with immunomodulatory therapies (with the exception of immunoglobulin and non-systemic and low-dose systemic corticosteroids)~* Recent use of investigational drugs or biologics, including those aimed at altering AD progression (with the exception of immunoglobulin)~* Active immunization for the treatment of AD at any time~There are reasons why it might not be appropriate to participate in this trial. Please contact Medical Information at medinfo@baxter.com for details.

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IGIV, 10% at 0.2 g/kg body weight (Type: EXPERIMENTAL): IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.
- IGIV, 10% at 0.4 g/kg body weight (Type: EXPERIMENTAL): IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).